摘要
尿激酶型纤溶酶原激活物受体(uPAR)是缺乏跨膜及胞浆部分的单链膜糖蛋白受体,通过糖基磷脂酰肌醇(GPI)锚定于细胞表面,在人体内广泛分布.
出处
《肿瘤》
CAS
CSCD
北大核心
2003年第1期81-83,共3页
Tumor
参考文献20
-
1[1]Andreasen PA, Kjoler L, Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: A review [J].Int J Cancer, 1997,72:l
-
2[2]Bell WR. The fibrinolytic system in neoplasia [J]. Semin Thromb Hemost, 1996,22:459
-
3[3]Dear AE, Medcalf RL. The urokinase-type-plasminogen-activator receptor(CD87) is a pleiotropic molecule [J]. Eur J Biochem, 1998,252:185
-
4[4]Ossowski L, Aguirre-Ghiso .JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth [J]. Curr Opin Cell Biol,2000,12:613
-
5[5]Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis:prognostic relevance and target for therapy [J]. Thromb Hemost,1997,78:285
-
6[6]Huang S, New L, Pan ZX, et al. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38α mitogenactivated protein kinase activity [J]. J Biol Chem,2000,275:12266
-
7[7]Del Vecchio S, Stoppelli MP, Carriero MV, et al. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels[J]. Cancer Res,1993,53:3198
-
8[8]Jard M, Ingl s-Esteve J, Burgal M, et al. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells[J]. Thromb Hemost, 1996,76:1009
-
9[9]Petro GD, Tavian D, Copeta A, et al. Expression of urokinase-type plasminogen activator (uPA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma [J]. Cancer Res,1998,58:2234
-
10[10]Duggan C, Maguire T, Mcdermott E, et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer[J]. Int J Cancer 1995,61:597
同被引文献45
-
1[1]Barry MA, Dower WJ, Johnston SA. Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries[J]. Nature Medicin, 1996, 2:299-305.
-
2[2]Szardenings M, Tornroth S, Mutulis F, et al. Phages display selection on whole cells yield a peptides specific for melanocortin receptor I[J]. J Bio Chem, 1997, 272:27943-27948.
-
3[4]范郎娣.卵巢癌临床与病理[M].天津:天津科学技术出版社,1993.153-164.
-
4[5]Ossowski L, Aguirre-ghiso JA. Urokinase receptor and integrin partnership:coordination of signaling for cell adhesion,migration and growth [J]. Curr Opin Cell Biol,2000,12: 613.
-
5[6]Andreasen PA, Egelund R , Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis [J]. Cell Mol Life Sci, 2000, 57:25.
-
6[7]Preissener KT, Knase SM, May AE. Urokinase receptor: a molecular organizer in cellular communication [J]. Curr Opin CHl Biol, 2000, 12:621.
-
7[8]Borgfildt C, Hansson SR, Gustavsson B , et al. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plaseminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1)[J].Int Cancer, 2001,92(4):479-502.
-
8Gerstein ES. Shcherbakov AI, Kazmin AI, et al. Urokinase and tissue type plasminogen activators and their typ-1 inhibitor(PAI-1) in gastric cancer[J]. Vopr Onkol. 2003, 49(2): 165-169.
-
9Horn LC, Pipping S, Raptis G. et al. Clinical relevance of urokinase type plasminogen activator and its inhibitor type I(PAI-1) in squamous cell carainoma of the uterine cervix[J].Aust J Obstet Gynaecol, 2002, 42(42): 383-386.
-
10Konno H, Abe J, Kaneko T. et al. Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer [J].Cance Res.2001,92(5): 516-523.
引证文献4
-
1张玉阳,帅茨霞,郑飞云.尿激酶型纤溶酶原激活物受体在上皮性卵巢癌中的表达及其意义[J].肿瘤学杂志,2004,10(5):305-306.
-
2张敬一,许顺江,史文海,张乃哲.实验性肺癌尿激酶型纤溶酶原激活物和抑制物的表达及意义[J].河北医科大学学报,2005,26(1):12-15.
-
3董欢,林燕苹,应学翔,何萍青.乳腺癌组织中uPA和PAI-1的表达及其临床意义[J].肿瘤,2013,33(4):361-367. 被引量:5
-
4宋国权,张迎泽,王璇.PLAUR基因过表达对人结肠癌细胞株CD133^+、CD44^+细胞增殖的影响[J].牡丹江医学院学报,2019,40(6):7-9. 被引量:1
二级引证文献6
-
1邹存华,王宏,宋冬冬,南平,盛梅.P38MAPK信号通路与uPA在卵巢癌细胞及组织中表达的相关性[J].中国癌症杂志,2015,25(8):572-578. 被引量:7
-
2张春霞,邹存华,宋冬冬,余江.P38MAPK信号通路对卵巢癌中尿激酶型纤维蛋白酶原激活剂的影响[J].山东大学学报(医学版),2016,54(2):68-74. 被引量:2
-
3王丽,杨帆,孔祥顺,刘运江,刘登湘.uPA、PAI-1组织表达与新辅助化疗治疗乳腺癌疗效及预后的相关性分析[J].解放军医药杂志,2016,28(6):33-35. 被引量:4
-
4庞岚,郑彦强,时志民,孙秀敏,刘石萍,杨俊英,张婕.UPA和MMP-9在子宫内膜癌组织中的表达情况及临床意义[J].现代中西医结合杂志,2016,25(32):3577-3579. 被引量:5
-
5邓卫东,李永红.CD44、HSPB1 rs2070804基因多态性与结肠癌病程的相关性[J].生物技术,2022,32(4):465-470. 被引量:1
-
6盛梅,张海燕,宋冬冬,邹存华.卵巢癌细胞及组织中P38MAPK信号通路调控uPA蛋白的表达及临床意义[J].肿瘤防治研究,2015,42(8):789-793. 被引量:5
-
1陈培杰,白培明.激素非依赖性前列腺癌细胞中EphA2表达的意义[J].中华泌尿外科杂志,2011,32(9):647-647.
-
2郑克文,李汉忠.基于前列腺干细胞抗原为靶点的肿瘤免疫治疗[J].协和医学杂志,2014,5(2):202-205. 被引量:1
-
3曲媛媛,徐向英.表皮生长因子受体与非小细胞肺癌放射敏感性相关的研究进展[J].中华放射医学与防护杂志,2011,31(4):504-507. 被引量:1
-
4杨营利,曹润福.CD24与肿瘤关系的研究进展[J].实用临床医学(江西),2007,8(11):135-136.
-
5李冬秀,吴小华,刘博君,曹瑾,吴艳霞,郝明.血清间皮素在卵巢上皮性癌诊断和病情监测中的价值[J].中华妇产科杂志,2010,45(4):307-310. 被引量:2
-
6肖宁(综述),艾文兵(校审).整合素拮抗剂治疗脑胶质瘤的研究进展[J].求医问药(下半月刊),2011,9(4):119-120.
-
7易平勇,余海,王青青,黄常新,李经忠,马文学.糖基磷脂酰肌醇锚定型小鼠B7.1融合蛋白的制备及抗肿瘤作用研究[J].中华微生物学和免疫学杂志,2004,24(12):955-959. 被引量:3
-
8王立萍,陈茜茜,袁庆民,汪淑晶.糖基化在肿瘤免疫中的作用[J].中国免疫学杂志,2017,33(2):297-300. 被引量:6
-
9陈景,黄香,宋海珠.CD73在肿瘤免疫治疗中的研究进展[J].癌症进展,2011,9(6):656-659. 被引量:1
-
10葛蕙心,张一兵,李慧忠,畅继武.GPI-B7-1锚定肾癌细胞膜对细胞毒性T淋巴细胞杀伤自身肿瘤的促进作用[J].山东医药,2016,56(29):7-10.